5:58 PM
 | 
Apr 01, 2009
 |  BC Extra  |  Company News

Altea in exenatide patch deal with Lilly, Amylin

Altea Therapeutics Corp. (Atlanta, Ga.) granted Eli Lilly and Co. (NYSE:LLY) and Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) exclusive, worldwide rights to develop and commercialize transdermal exenatide using Altea's PassPort Transdermal...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >